PT-141 Bremelanotide Evidence and Labeled Dosing

PT-141 is bremelanotide, a melanocortin receptor agonist sold as Vyleesi.¹ The approved indication covers acquired, generalized hypoactive sexual desire disorder in premenopausal women. It explicitly excludes men and sexual-performance enhancement.¹ One 2008 trial reported positive results in men with erectile dysfunction who had not responded to sildenafil, but it studied an intranasal formulation. The approved product uses a different route in a different population.^1,3

Regulatory Status of PT-141

The approved indication for PT-141 does not include men. The FDA prescribing information for Vyleesi states:

> "VYLEESI is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is NOT due to: A co-existing medical or psychiatric condition, Problems with the relationship, or The effects of a medication or drug substance."

> "VYLEESI is not indicated for the treatment of HSDD in postmenopausal women or in men."

> "VYLEESI is not indicated to enhance sexual performance."¹

For a man offered compounded PT-141, the proposed treatment is an off-label use of bremelanotide. The approved indication excludes men, and the sources available here report no outcomes with compounded PT-141.

Bremelanotide is a melanocortin receptor agonist.¹ The peptide therapy overview explains that mechanism in more detail. If PT-141 is offered to you, ask which formulation is being prescribed and how the evidence applies to your symptoms.

Label Dosing for the Approved Population

The published PT-141 dosage belongs to Vyleesi's approved population. It is not a dosing protocol for men.

The label specifies the following for premenopausal women with acquired, generalized hypoactive sexual desire disorder:

• A 1.75 mg subcutaneous injection delivered by autoinjector
• Injection in the abdomen or thigh
• Administration at least 45 minutes before anticipated sexual activity
• No more than one dose within 24 hours
• No more than eight doses per month recommended¹

No source listed here establishes a PT-141 dosage for men. The 2008 men's trial used a different dose and an intranasal formulation, so its regimen cannot be converted into instructions for the approved injectable product.³ Compounded dosing belongs with the prescriber responsible for the treatment plan.

Side Effects of PT-141 Under the Label

Nausea is the most common adverse reaction in the Vyleesi prescribing information. It was reported in 40% of patients and typically began within one hour. The label reports that nausea lasted about two hours.¹

Other common PT-141 side effects were:

• Flushing: 20.3%
• Injection site reactions: 13.2%
• Headache: 11.3%
• Vomiting: 4.8%¹

The label also reports transient blood pressure increases. Peak changes were 6 mmHg systolic and 3 mmHg diastolic, with the increases resolving within 12 hours.¹

These figures come from the approved product's evidence in women. They should not be presented as measured rates in men using compounded PT-141. Your prescriber should review the nausea rate, blood pressure changes, and formulation before deciding whether off-label treatment belongs in your plan.

Clinical Evidence in Women and Men

The evidence in women and men comes from different formulations, populations, and research programs.

Evidence Factor	Phase 3 Trials in Women	2008 Trial in Men
Population	Premenopausal women with hypoactive sexual desire disorder	Married men aged 28 to 59 with erectile dysfunction who had not responded to sildenafil
Study design	Two randomized, double-blind, placebo-controlled trials	One randomized, double-blind, placebo-controlled trial
Formulation	Subcutaneous bremelanotide	Intranasal bremelanotide
Main finding	Increased sexual desire and reduced distress	Positive clinical results in 33.5% with bremelanotide and 8.5% with placebo
Evidence boundary	Supports the approved population and route	Does not establish dosing or outcomes for injectable PT-141 in men

The two RECONNECT phase 3 trials randomized 1,267 women. Participants had a mean age of 39, and 85.6% were white.²

Bremelanotide produced statistically significant increases on the Female Sexual Function Index desire domain. The changes were 0.30 in study 301, 0.42 in study 302, and 0.35 in the integrated analysis. Each result had a P value below .001.² The trials also reported statistically significant reductions in distress related to low sexual desire.² The absolute changes on the desire domain were small even though they reached statistical significance.

The men's evidence comes from one trial published in 2008. It enrolled 342 married men aged 28 to 59 who had erectile dysfunction and had not responded to sildenafil. Participants received either intranasal bremelanotide 10 mg or placebo.³

Positive clinical results occurred in 33.5% of the bremelanotide group and 8.5% of the placebo group, with a P value of .03. Intercourse satisfaction was also higher in the bremelanotide group, while drug-related adverse effects occurred more often.³

That trial studied sildenafil non-responders, used an intranasal formulation, and was published in 2008. The approved product is subcutaneous and indicated for a different population. No source here compares bremelanotide head-to-head with Viagra or Cialis, so a physician weighs the mechanistic difference against your symptoms rather than ranking the two.

Physician Review for Men's Off-Label Use

A physician first needs to define the symptom you want treated. The Vyleesi label addresses low desire in premenopausal women, while the 2008 men's trial studied erectile dysfunction after sildenafil failure.^1,3

If desire is the concern, the clinical discussion should focus on decreased libido and low libido in men. If erection quality is the concern, the erectile dysfunction overview and causes of ED address that condition without treating one symptom as the whole picture.

Your physician should review existing conditions, current medications, blood pressure, and the proposed PT-141 formulation. The discussion should also cover the approved indication, the limits of the men's trial, and the 40% nausea rate in the label.^1,3 Bring the exact product and formulation to that conversation so the decision is tied to the treatment being offered.

GHK-Cu is the other peptide on this site where the human evidence and the marketing claims sit some distance apart.

The Opt Take on PT-141

At Opt Health, a physician interprets your labs against your symptoms, existing conditions, and current medications. The physician then builds your plan and adjusts it after repeat testing. Our care model begins with more than 55 biomarkers, followed by a one-on-one physician consultation.

PT-141 should not enter a plan based on a dosage chart or a single symptom. Low libido, erectile dysfunction, hormone levels, metabolic markers, sleep, and medication use can form different clinical patterns. Your physician needs that pattern before considering a treatment whose approved indication excludes men.

Get started: Begin with Opt Health, where a physician reads your labs, builds your plan, and adjusts it over the loop.

Frequently Asked Questions

This content is for informational purposes and does not replace evaluation, diagnosis, or treatment by a qualified medical professional.